Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Merus still hopes for a future for MCLA-129, but the doors are closing.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.